Smith & Nephew plc (LON:SN - Get Free Report) insider Sybella Stanley acquired 3,810 shares of the firm's stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of GBX 1,101 ($14.24) per share, for a total transaction of £41,948.10 ($54,238.56).
Smith & Nephew Stock Up 0.4 %
Shares of LON:SN traded up GBX 4 ($0.05) on Monday, hitting GBX 1,071 ($13.85). 1,639,303 shares of the company traded hands, compared to its average volume of 343,671. The company has a market capitalization of £11.74 billion, a P/E ratio of 38.56, a PEG ratio of 0.46 and a beta of 0.62. The business has a 50 day moving average price of GBX 1,070.03 and a 200 day moving average price of GBX 1,050.37. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22.
Smith & Nephew Increases Dividend
The firm also recently declared a dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Thursday, March 27th will be given a dividend of $0.23 per share. The ex-dividend date is Thursday, March 27th. This represents a dividend yield of 1.61%. This is a positive change from Smith & Nephew's previous dividend of $0.14. Smith & Nephew's dividend payout ratio is presently 104.41%.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. reissued an "overweight" rating and set a GBX 1,180 ($15.26) price objective on shares of Smith & Nephew in a research report on Tuesday, January 14th.
Check Out Our Latest Report on SN
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Read More
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
